Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-08-18
1999-11-09
Gupta, Yogendra N.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514212, 514242, 514255, 514274, 540524, 544182, 544316, 544405, 546122, A61K 31445, C07D47104
Patent
active
059815469
ABSTRACT:
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
REFERENCES:
patent: 5260277 (1993-11-01), McKenzie
patent: 5455243 (1995-10-01), Duggan et al.
patent: 5534524 (1996-07-01), Bonewald et al.
patent: 5668159 (1997-09-01), Jin et al.
Askew Ben C.
Coleman Paul J.
Duggan Mark E.
Hartman George D.
Hoffman William F.
Durettte Philippe L.
Gupta Yogendra N.
Merck & Co. , Inc.
Sabatelli Anthony D.
Winokur Melvin
LandOfFree
Integrin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456420